Showing 3661-3670 of 9151 results for "".
- FDA Clears Candela's Vbeam 595 nm Pulsed Dye Laser for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Populationhttps://practicaldermatology.com/news/fda-clears-vbeam-595-nm-pulsed-dye-laser-for-the-treatment-of-port-wine-stains-and-hemangiomas-in-the-pediatric-population/2461824/The U.S Food and Drug Administration has cleared candela’s Vbeam family of 595 nm wavelength pulsed dye lasers (PDL) to treat cutaneous capillary malformations, and infantile hemangiomas (IH)/congenital hemangiomas in the pediatric population (from birth – 21 years of age).
- News Your Patients Can Use: AAD Offers Sun Protection Counsel in Advance of Independence Day Holiday Weekendhttps://practicaldermatology.com/news/news-your-patients-can-use-aad-offers-sun-protection-counsel-in-advance-of-independence-day-holiday-weekend/2461819/Remind your patients to use sunscreen on the July 4th weekend and on the days, weeks, and months that follow. A recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults revealed that one-third of American parents reported having a child who
- US FDA Nod for Pfizer's Alopecia Drughttps://practicaldermatology.com/news/us-fda-nod-for-pfizers-alopecia-drug/2461814/The US Food and Drug Administration (FDA) approved Litfulo (ritlecitinib, Pfizer Inc) for severe alopecia areata in individuals 12 years of age and older. A kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) f
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to
- National Rosacea Society Offers New Seal of Acceptancehttps://practicaldermatology.com/news/national-rosacea-society-offers-new-seal-of-acceptance/2461801/The National Rosacea Society is launching a Seal of Acceptance program to identify skin care and cosmetic products that may be suitable for people with rosacea. “One of the most common requests the Society receives from rosacea patients is for info
- Cedric Burg Named New COO at Innovadermhttps://practicaldermatology.com/news/cedric-burg-named-new-coo-at-innovaderm/2461798/Cedric Burg is Innovaderm’s new Chief Operating Officer. Mr. Burg’s new role entails the management of Innovaderm’s global operations in Canada, through the close collaboration between department heads while overseeing most of Innovaderm’s activi
- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- Breaking Business News: Lilly to Acquire DICE Therapeuticshttps://practicaldermatology.com/news/breaking-business-news-lilly-to-acquire-dice-therapeutics/2461796/Eli Lilly and Company will acquire DICE Therapeutics, Inc. for a cool $2.4 billion to expand its immunology pipeline. DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic c
- Almirall Launches New Series Highlighting the Impact of Psoriasis on Wellbeinghttps://practicaldermatology.com/news/almirall-launches-new-series-highlighting-the-impact-of-psoriasis-on-wellbeing/2461795/Almirall has launched Nina, a three-episode series about the life of a fashion designer with psoriasis to illustrate a journey from darkness to light. Nina narrates the story of an introverted designer portrayed by Spanish actress Alba Ribas (Cable Girls, Netflix). One da